Category: Include on Menu
-
Gold Pulls Back as Investors Track Developments in Iran Ceasefire Talks
Gold prices declined on Tuesday, surrendering much of the previous session’s advance as traders continued to assess developments surrounding a potential ceasefire between the United States and Iran. The precious metal swung between gains and losses before slipping to around $4,538 an ounce. President Donald Trump said on Monday that he had approved a new…
-
Nickel prices advance amid Indonesia supply concerns after production curbs
Nickel prices moved higher on Tuesday as the market reacted to potential supply disruptions in Indonesia, the world’s largest nickel producer, following reports that Tsingshan Group had instructed nickel pig iron producers at its Weda Bay industrial complex to scale back output. Three-month nickel on the London Metal Exchange rose 0.4% to $18,567 per metric…
-
Trump’s Iran Remarks Lift Hopes for Peace Deal as Markets Track Oil and AI Momentum: Dow Jones, S&P, Nasdaq, Wall Street Futures
U.S. futures trade cautiously ahead of key earnings U.S. stock futures were little changed early Tuesday as investors weighed renewed optimism over a possible peace agreement between the United States and Iran while preparing for major technology earnings later this week. At 03:30 ET, Dow futures were broadly flat, S&P 500 futures slipped 0.1%, and…
-
Rising Treasury Yields and Iran Tensions Weigh on Tech to Start the Week
Wall Street kicked off the trading week on an uneven note Monday as rising bond yields and ongoing geopolitical uncertainty surrounding Iran kept buyers cautious. The Dow Jones Industrial Average managed a modest gain, but the tech-heavy Nasdaq slipped as higher rates pressured growth stocks. Investors appeared content to stay on the sidelines ahead of…
-
Positive Nu-3 Data Advances Lakewood-Amedex Toward Phase 2 Diabetic Foot Ulcer Trial (LABT)
Manufacturing progress, stability data, and formulation advances are moving Lakewood-Amedex’s lead antimicrobial candidate closer to Phase 2 testing in infected diabetic foot ulcers. Key Investor Takeaways Why LABT Stock Is in Focus Lakewood-Amedex Biotherapeutics announced positive development and manufacturing data for Nu-3, its lead antimicrobial candidate targeting mildly infected diabetic foot ulcers. According to the…
-
AI Robotics MOU Expands Nature’s Miracle Beyond Agriculture Infrastructure (NMHI)
A new robotics-focused partnership could broaden Nature’s Miracle’s exposure to AI automation, industrial robotics, and smart infrastructure markets beyond its core controlled-environment agriculture business. Key Investor Takeaways Why Nature’s Miracle Holding Stock Is in Focus Nature’s Miracle Holding announced that it signed a Memorandum of Understanding with DROMNI Intelligence Technology to collaborate on autonomous robotics…
-
Tirzepatide Combination Study Expands Clearmind’s Obesity Therapy Strategy (CMND)
A new preclinical research agreement positions Clearmind Medicine to evaluate whether MEAI could complement or extend the effects of blockbuster GLP-1 obesity therapies such as tirzepatide. Key Investor Takeaways Why Clearmind Medicine Stock Is in Focus Clearmind Medicine announced a new research agreement with Yissum Research Development Company of the Hebrew University of Jerusalem to…
-
CEO Appointment Signals Commercial Expansion Push for Brenmiller Energy’s BNRG360 Strategy (BNRG)
Brenmiller Energy’s leadership transition comes as the company increases its focus on scaling thermal energy storage commercialization and industrial decarbonization solutions. Key Investor Takeaways Why Brenmiller Energy Stock Is in Focus Brenmiller Energy announced that its board appointed Nir Brenmiller as Chief Executive Officer, replacing Avi Brenmiller in the CEO role while Avi remains Chairman…
-
Adjusted Net Income Surge Highlights Improving Tanker Market Exposure for C3is (CISS)
Strong charter rates, rising cash flow, and expanding exposure to the product tanker market pushed C3is to sharply higher adjusted earnings in the first quarter of 2026. Key Investor Takeaways Why C3is Stock Is in Focus C3is reported first-quarter 2026 revenue of $11.6 million, up 34% from the prior-year period, while adjusted net income climbed…
-
Immortalized Silk Gland Cell Line Breakthrough Expands Kraig Biocraft’s Biotech Ambitions (KBLB)
A newly developed immortalized silkworm silk gland cell line could broaden Kraig Biocraft Laboratories’ reach beyond spider silk textiles into recombinant proteins, therapeutics, and industrial biotechnology applications. Key Investor Takeaways Why KBLB Stock Is in Focus Kraig Biocraft Laboratories announced that its research team successfully developed an immortalized silk gland cell line, which the company…